News and Announcements
Arthritis Relief Plus Annual Update 2016; US FDA Compliance Completed, Australian Government Support & First Commercial Batch in US
- Published January 17, 2017 5:08PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Arthritis Relief Plus Ltd (ARP) attained countless achievements during 2016.
- The company managed to complete US FDA compliance, securing an OTC topical drug status/ classification for 4Jointz.
- With also securing Australian Government support in the first cohort at the Rocketspace LandingPad in San Francisco.
- ARP also were awarded the Queensland Government Ignite grant, with commencing production of the first commercial batch of 4 Jointz in the USA.
- ARP also received to its advantage, national and regional broadcasting news coverage of its product throughout Australia.
- Finally, ARP secured a new investment offer which opened to fund the USA market growth and prepare for the global market partnering/licensing activities.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
